Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
| ▸ | TLR4 | O00206 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25236899 | 0.88 | ALDH1A1 (0.37) | ALDH1A1TSHRNOS1HSD17B10MAPT | |
| SCHEMBL5567324 | 0.81 | TSHR (0.37) | ALDH1A1TSHRNOS1HSD17B10KDM4E | |
| SCHEMBL8310026 | 0.76 | ALDH1A1 (0.42) | ALDH1A1MAPTKDM4ECYP2C19GAA | |
| SCHEMBL4329985 | 0.75 | ALDH1A1 (0.56) | ALDH1A1TSHRPDE10AMAPTKDM4E | |
| SCHEMBL30473086 | 0.75 | ALDH1A1 (0.56) | ALDH1A1TSHRPDE10AMAPTKDM4E | |
| SCHEMBL25421963 | 0.75 | ALDH1A1 (0.37) | ALDH1A1SCN9ATSHRPDE10AMAPT | |
| SCHEMBL25272854 | 0.75 | NOS1 (0.39) | ALDH1A1NOS1PDE10AMAPTKDM4E | |
| SCHEMBL3997861 | 0.74 | LMNA (0.46) | ALDH1A1TSHRMEN1KMT2ALMNA | |
| SCHEMBL18921106 | 0.73 | MEN1 (0.52) | ALDH1A1TSHRNOS1HSD17B10PDE10A | |
| SCHEMBL1371678 | 0.73 | MEN1 (0.50) | ALDH1A1TSHRNOS1HSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4448492-B1 | COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | REGLAGENE INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12404242-B2 | Compositions and methods for making and using small molecules in the treatment of cancer | REGLAGENE, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250109105-A1 | COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | REGLAGENE, INC. | 2025-04-03 | — | — | US | disclosed |
| EP-4448492-A1 | COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | Reglagene, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023111996-A1 | COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | REGLAGENE HOLDING, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20070232607-A1 | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases | BRADBURY ROBERT H | 2007-10-04 | — | — | US | disclosed |
| EP-1756088-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005118572-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109105-A1 | COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | CD47, RB1, TP53 | ALDH1A1 1334/4885SCN9A 4677/4885TSHR 3995/4885 |
| US-12404242-B2 | Compositions and methods for making and using small molecules in the treatment of cancer | CD47, RB1, TP53 | ALDH1A1 1334/4885SCN9A 4677/4885TSHR 3995/4885 |
| US-20070232607-A1 | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases | ERBB2, ERBB3, ERBB4 | ALDH1A1 3782/4885SCN9A 2906/4885TSHR 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.